We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Plans to Get Tough on Poor Data Integrity

FDA Plans to Get Tough on Poor Data Integrity

July 18, 2014

The FDA intends to step up its scrutiny of a company’s data integrity protections during manufacturing inspections, following a series of investigations that caught drugmakers backdating manufacturing records and falsifying data.

The FDA is focusing on the issue because a single data integrity issue calls into question all the data produced by a company, FDA officials said.

Investigators are already citing an increasing number of drugmakers for data integrity failures, with non-U.S. facilities experiencing most of the problems, agency representatives said at the Food and Drug Law Institute’s current good manufacturing practices conference in Washington, D.C.

In fiscal year 2013, eight of the 26 warning letters the agency issued to foreign manufacturers cited data integrity. In 2014, 12 of 13 warning letters issued to date have found problems with data integrity.

Alicia Mozzachio, chief of the international compliance branch of the Office of Manufacturing and Product Quality, said the top data integrity issues observed during inspections are:

  • Not recording activities contemporaneously;
  • Backdating documents. The agency response to this varies depending on the document in question. For example, a one-time backdating of an equipment calibration record may not be as severe as backdating a record of an analytical test method, said Mozzachio;
  • Fabricating data. Outright fabrication of data can be extremely challenging for FDA investigators to detect, she said, and is treated very seriously by the agency; and
  • Copying data from past records and fraudulently reporting it as new data.

Once such activities are uncovered, the FDA demands rigorous efforts to prove a company has corrected its problems. The best way for a company to get back into compliance is to conduct a comprehensive audit of the data controls in its systems, said Thomas Cosgrove, acting director of the Office of Manufacturing and Product Quality, and conduct ongoing review to ensure changes are effective.

“We want to see sustained periods of reliable data,” Cosgrove said after the session. “What we are looking to avoid is quick fixes that don’t reflect true underlying changes.”

The FDA has started to emphasize in warning letters the importance of hiring third-party auditors to conduct such data integrity reviews, Mozzachio added.

Last month, for example, the FDA recommended Canadian generics maker Apotex conduct such an audit of its plant in Bangalore, India, when it issued a warning letter citing rampant problems with data manipulation, including continuously retesting batches until the desired result is achieved.

“If it’s not written down, it didn’t happen” —that’s how the FDA thinks. Get drug GDP training right — the first time, purchase Good Documentation Practices today!

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

  • Eli Lilly logo

    Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

  • CE mark

    Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing